Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes

Postgraduate Medical Journal

Volumn 81, Issue 951, 2005, Pages 1-6

  Tushuizen, M E ^a   Diamant, M ^a   Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIUM; EPIDEMIC; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL STATE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; POSTPRANDIAL PERIOD; RISK FACTORS;

EID: 13244268615     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.020511     Document Type: Review

References (64)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. DeFronzo RA. Pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: a balanced overview. Diabetologia 1992;35:389-97.
3. Dunaif A. Insulin resistance and the polycystic ovarian syndrome: mechanisms and implications for pathogenesis. Endocr Rev 1997;18:774-800.
4. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
5. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
6. Lusis A. Atherosclerosis. Nature 2000;407:233-41.
7. Widlansky ME, Gokce N, Keaney JF Jr, et al. The clinical implications of endothelial dysfunction. J Am Coll Cordial 2003;42:1149-60.
8. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of me International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65.
9. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA 2003;290:932-40.
10. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002;22:1649-54.
11. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16:125-32.
12. Heberden W. Some account of a disorder of the breast. Med Trans 1772;2:59-67.
13. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-85.
14. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998;19:583-92.
15. Heine RJ, Dekker JM. Beyond postprandial hvperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002;45:461-75.
16. Mero N, Malmstrom R, Steiner G, et al. Postprandial metabolism of apolipoprotein B-48- and B-100-containing particles in type 2 diabetes mellitus: relations to angiographically verified severity of coronary artery disease. Atherosclerosis 2000;150:167-77.
17. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
19. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
20. DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group, Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-21.
21. Thalhammer C, Balzuweit B, Busjahn A, et al. Endothelial cell dysfunction and arterial wall hypertrophy are associated with disturbed carbohydrate metabolism in patients at risk for cardiovascular disease. Arterioscler Thromb Vasc Biol 1999;19:1173-9.
22. Kawano H, Motoyama T, Hiroshima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
23. Ceriello A, Falleti E, Motz E, et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:146-9.
24. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-25.
25. Ceriello A, Giacomello R, Stel G, et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes 1995;44:924-8.
26. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003;41:1013-20.
27. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation 2002;106:2067-72.
28. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial function in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-50.
29. Shizukuda Y, Reyland ME, Buttrick PM. Protein kinase C-delta modulates apoptosis induced by hyperglycemia in adult ventricular myocytes. Am J Physiol Heart Circ Physiol 2002;282:H1625-34.
30. Risso A, Mercuri F, Quagliaro L, et al. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab 2001;281:E924-30.
31. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
32. Bos G, Dekker JM, Nijpels G, et al. A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism - The Hoorn Study. Diabetologia 2003;46:910-6.
33. Meigs JB, Nathan DM, D'Agostino RB Sr, et al. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002;25:1845-50.
34. Taskinen MR. Diabetic dyslipidemia: from basic research to clinical practice. Diabetologia 2003;46:733-49.
35. Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med 1959;103:4-8.
36. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
37. Groot PH, Van Stiphout WA, Krauss XH, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991;11:653-62.
38. Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-8.
39. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diabetes Care 2000;23:1401-6.
40. Lewis GF, O'Meara NM, Soltys PA, et al. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. J Clin Endocrinol Metab 1991;72:934-44.
41. Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
42. Anderson RA, Evans ML, Ellis GR, et al. The relationships between post-prandial lipaemia, endothelial function and oxidative stress in healthy individuals and patients with type 2 diabetes. Atherosclerosis 2001;154:475-83.
43. Plotnick GD, Correti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA 1997;278:1682-6.
44. Moers A, Fenselau S, Schrezenmeir J. Chylomicrons induce E-selectin and VCAM-1 expression in endothelial cells. Exp Clin Endocrinol Diab 1997;105(suppl 2):35-7.
45. Lundman P, Tornvall P, Nilsson L, et al. A triglyceride-rich fat emulsion and free fatty acids but not very low densitiy lipoproteins impair endothelium-dependent vasorelaxation. Atherosclerosis 2001;159:35-41.
46. Silveira A, Karpe F, Johnsson H, et al. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arterioscler Thromb Vasc Biol 1996;16:1333-9.
47. Silva KR, Kelly CN, Jones AE, et al. Chylomicron particle size and number, factor VII activation and dietary monounsaturated fatty acids. Atherosclerosis 2003;166:73-84.
48. Byrne CD, Wareham NJ, Martensz ND, et al. Increased PAI activity and PAI-1 occuring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels. Atherosclerosis 1998;140:45-53.
49. Broijersen A, Karpe F, Hamsten A, et al. Alimentary lipemia enhances the membrane expression of platelet P-selectin without affecting other markers of platelet activation. Atherosclerosis 1998;137:107-13.
50. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001;24:73-7.
51. Heinemann L, Klappoth W, Rave K, et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000;23:1343-7.
52. Thompson RG, Pearson L, Schoenfeld SL, et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group. Diabetes Care 1998;21:987-93.
53. Chiasson JL, Josse RG, Gomis R, et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
54. Baron AD, Eckel RH, Schmeiser L, et al. The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism 1987;36:409-15.
55. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33.
56. Jeppesen J, Zhou MY, Chen YD, et al. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994;17:1093-9.
57. Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev 2002;18:484-90.
58. Kudlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study. Horm Metab Res 1992;24:478-83.
59. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
60. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
61. Karpe F. Postprandial lipemia-effect of lipid-lowering drugs. Atherosclerosis 2002;suppl:41-6.
62. Bae JH, Bassenge E, Lee HJ, et al. Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates. Atherosclerosis 2001;158:165-71.
63. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Circulation 2002;106:1211-8.
64. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003;91:9B-13.